Trial Search Results

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

AstraZeneca

Stanford Investigator(s):

Intervention(s):

  • Drug: Budesonide/formoterol pMDI
  • Drug: Formoterol Turbuhaler

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - A clinical diagnosis of COPD with symptoms for more than 2 years.

   - Smoking history of 10 or more pack years

   - A history of at least one COPD exacerbation requiring a course of oral steroids and/or
   antibiotics within 1-12 months before first visit.

Exclusion Criteria:

   - A history of asthma

   - Patients taking oral steroids

   - Any significant disease or disorder that may jeopardize the safety of the patient

Ages Eligible for Study

40 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ware Kuschner
6504935000 x 63544
Not Recruiting